PDF - Presentation for Media & Analysts - Acino
PDF - Presentation for Media & Analysts - Acino
PDF - Presentation for Media & Analysts - Acino
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Segment Technology Marketing<br />
Focus: Partnerships/co-developments with<br />
leading pharmaceutical cos. based on <strong>Acino</strong>’s<br />
strong and leading technology plat<strong>for</strong>ms<br />
Drug delivery solutions <strong>for</strong> new NCE’s<br />
Life cycle management<br />
Contract manufacturing / customer usually owns IP<br />
TM sales +67% yoy<br />
Contribution margin -48% yoy to 5.9% of sales<br />
(2011: 18.9%)<br />
Includes fentanyl contract manufacturing (not own IP)<br />
Negatively impacted by price pressure and betalactame<br />
production in Liesberg (to be discontinued by end 2013)<br />
Production <strong>for</strong> Teva/Mepha out of Aesch<br />
Low margin, supports capacity utilization and overhead<br />
recovery<br />
Expected to decrease over the next years, to be<br />
replaced by higher margin products<br />
12
Change language